683 Capital Management’s Elicio Therapeutics ELTX Stock Holding History

683 Capital Management’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$603K	Hold	56,442	–	–	0.03%	173
2025 Q4	$449K	Buy	+56,442	New	+$512K	0.02%	199

Other funds holding ELTX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

683 Capital Management's ELTX Position: Q1 2026 in Review

683 Capital Management held its Elicio Therapeutics (ELTX) position steady in Q1 2026 at 56,442 shares worth $603K. The position accounts for 0.03% of the portfolio, ranked #173.

683 Capital Management first reported a position in ELTX in Q4 2025 and has held it in 2 quarters since. 47 funds tracked by Wall St. Rank hold ELTX as of Q1 2026.

683 Capital Management held 56,442 shares of Elicio Therapeutics worth $603K as of Q1 2026.
683 Capital Management left its Elicio Therapeutics share count unchanged in Q1 2026.
Elicio Therapeutics made up 0.03% of 683 Capital Management's portfolio in Q1 2026, its #173 holding.
683 Capital Management first reported a position in Elicio Therapeutics in Q4 2025 and has held it in 2 quarters since.
47 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.